Skip to content

Effect of dexamethasone injection into Neiguan acupoint combined with percutaneous acupoint electrical stimulationin preventing nausea and vomiting after gynecological laparoscopic surgery

Effect of dexamethasone injection into Neiguan acupoint combined with percutaneous acupoint electrical stimulationin preventing nausea and vomiting after gynecological laparoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078920
Enrollment
Unknown
Registered
2023-12-21
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting

Interventions

Group 1:Dexamethasone is injected into the Neiguan acupoint
Group 2:Transcutaneous electrical stimulation of acupuncture points
Group 3:Dexamethasone is injected into Neiguan acupoint combined with percutaneous electrical stimulation of acupoints
Group 4:Only stick the electrode piece without stimulation
Inject 1ml of normal saline 2cm next to the Neiguan acupoint

Sponsors

First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Patients eligible for this study are aged 18 years or older and no more than 65 years old;(2) The American Society of Anesthesiology (ASA) anesthesia risk scale Class I - Class III;(3)30 kg/m2 = body mass index(BMI) >18kg/m2;(4)Patients provide voluntary informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients with implantable medical devices such as pacemakers;(2)Patients with infection at the injection site of acupuncture points or severe systemic infection;(3)Coagulation disorders;(4)Patients with needle sickness;(5)Patients who have received percutaneous electrical stimulation or acupoint injection in the past month;(6)Combined psychiatric illness and inability to cooperate;(7)Hemoglobin less than 90 g/L; (8) Severe hepatic and renal insufficiency ; (9)NYHA classification of cardiac function=grade 3;(10)vascular lesions of the extremities; (11)A history of chemoradiotherapy for malignant tumors in the past 4 weeks;(12)Nausea, vomiting, or both within 24 hours prior to surgery;(13)Antiemetics,ioids or glucocorticoids are used 24 hours before surgery.

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting within 24 hours after surgery;Postoperative Complications;

Secondary

MeasureTime frame
Severity of nausea and vomiting within 24 hours after surgery and incidence of clinically severe nausea and vomiting (based on the PONV scale developed by Myles);Anesthesia time and operation time;Pain score;Cumulative amount of salvage antiemetic medication used within 48 hours after surgery;

Countries

China

Contacts

Public ContactPeng Lihua

First Affiliated Hospital of Chongqing Medical University

plhcqmu@163.com+86 158 2344 3968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026